-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Since the beginning of July, companies have released their 2022 semi-annual financial repor.
As of July 25, many multinational pharmaceutical companies have also announced their financial reports for the first half of 2022, and many companies have handed over satisfactory "response.
For example, according to Roche's performance in the first half of 2022 disclosed on July 21, Roche's total revenue in the first half of the year increased by 5% year-on-year to 3295 billion Swiss francs; net profit increased by 12% year-on-year to 161 billion Swiss fran.
Its growth rate comes from the diagnostics sector, with data showing that in the first half of the year, revenue from its diagnostics business increased by 10% year-on-year to CHF 948 billi.
Additionally, its POCT revenue grew 45% in the first half of the ye.
Molecular POCT business grew 54%, while POCT immunodiagnostics business grew 7
Roche expects group sales to remain stable or grow by low single digits in 202On July 19, Johnson & Johnson released its financial data for the first half of 2022, showing that in the first half of 2022, Johnson & Johnson’s total global revenue was US$4446 billion, a year-on-year increase of 4%, and its net profit was US$963 billion, a year-on-year decrease of 2
According to the sales data in the first half of the year, the revenue of the pharmaceutical business was US$2186 billion, a year-on-year increase of 5%; the revenue of the medical device business was US$1869 billion, a year-on-year increase of 3%; consumpti.
The announcement shows that the strong growth of Johnson & Johnson's pharmaceutical business is mainly due to Stelara (ustekinumab), Darzalex (daratumumab), Imbruvica (ibrutinib), Tremfya (gusekinumab), Erleada (Apalutamide) and several other produc.
It is reported that in November last year, Johnson & Johnson announced a new spin-off plan, in order to implement a more targeted business strategy and accelerate growth, divest its sales of Band-Aid (Band-Aid), Tylenol (Tylenol) drugs and Johnson & Johnson Baby Refre.
Powder (Johnson's Baby Powder) consumer health busine.
On July 19, Novartis also announced its results for the first half of 202 According to the data, Novartis’ net sales revenue in the first half of the year reached US$2312 billion, which was basically the same as the previous ye.
Net profit was US$914 billion, down 21% year-on-ye.
Among them, China contributed US$6 billion in revenue, an increase of 11% year-on-year, mainly driven by Cosent.
The data shows that the net sales of Novartis branded innovative drugs were US$26 billion, mainly from Entresto (sacubitril + valsartan), Kesimpta (ofatumumab), Cosentyx (secukinumab), Kisqali Driven by strong growth in products such as (Liberxilli) and Zolgens.
In terms of specific varieties, the sales of the blockbuster immune drug Cosentyx in the first half of the year reached US$434 billion, a year-on-year increase of 9%; the sales of the anti-heart failure drug Entresto in the first half of the year reached US$218 billion, a year-on-year increase of 32%; these two varieties are still The key drugs driving Novartis' performance grow.
In addition, Sandoz's generics business reported first-half net sales of $7 billion (-1.
In addition, on July 20, Abbott announced its results for the second quarter of 2022, with revenue of $1257 billion, a year-on-year increase of 11%, and net profit of $018 billion, a year-on-year increase of 6In addition, according to its first-quarter 2022 results announced in June, revenue was US$19 billion, a year-on-year increase of 18%; the company's net profit was US$447 billion, a year-on-year increase of 3
Looking ahead, Abbott raised its full-year 2022 EPS guidan.
Abbott expects full-year diluted earnings per share of at least $50 on a GAAP bas.
Adjusted (excluding charges for special items) diluted earnings per share was at least $Abbott also expects testing-related revenue to reach $1 billion for the full year 2022, including $6 billion in sales through June 2022 and $500 million in sales over the next few mont.
According to Biogen’s financial report for the first half of 2022, the company’s total revenue in the first half of 2022 was US$121 billion, down 4% year-on-year; net profit was US$277 billion, down 17% year-on-year; R&D investment was US$08 billion, down 7% year-on-year.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
As of July 25, many multinational pharmaceutical companies have also announced their financial reports for the first half of 2022, and many companies have handed over satisfactory "response.
For example, according to Roche's performance in the first half of 2022 disclosed on July 21, Roche's total revenue in the first half of the year increased by 5% year-on-year to 3295 billion Swiss francs; net profit increased by 12% year-on-year to 161 billion Swiss fran.
Its growth rate comes from the diagnostics sector, with data showing that in the first half of the year, revenue from its diagnostics business increased by 10% year-on-year to CHF 948 billi.
Additionally, its POCT revenue grew 45% in the first half of the ye.
Molecular POCT business grew 54%, while POCT immunodiagnostics business grew 7
Roche expects group sales to remain stable or grow by low single digits in 202On July 19, Johnson & Johnson released its financial data for the first half of 2022, showing that in the first half of 2022, Johnson & Johnson’s total global revenue was US$4446 billion, a year-on-year increase of 4%, and its net profit was US$963 billion, a year-on-year decrease of 2
According to the sales data in the first half of the year, the revenue of the pharmaceutical business was US$2186 billion, a year-on-year increase of 5%; the revenue of the medical device business was US$1869 billion, a year-on-year increase of 3%; consumpti.
The announcement shows that the strong growth of Johnson & Johnson's pharmaceutical business is mainly due to Stelara (ustekinumab), Darzalex (daratumumab), Imbruvica (ibrutinib), Tremfya (gusekinumab), Erleada (Apalutamide) and several other produc.
It is reported that in November last year, Johnson & Johnson announced a new spin-off plan, in order to implement a more targeted business strategy and accelerate growth, divest its sales of Band-Aid (Band-Aid), Tylenol (Tylenol) drugs and Johnson & Johnson Baby Refre.
Powder (Johnson's Baby Powder) consumer health busine.
On July 19, Novartis also announced its results for the first half of 202 According to the data, Novartis’ net sales revenue in the first half of the year reached US$2312 billion, which was basically the same as the previous ye.
Net profit was US$914 billion, down 21% year-on-ye.
Among them, China contributed US$6 billion in revenue, an increase of 11% year-on-year, mainly driven by Cosent.
The data shows that the net sales of Novartis branded innovative drugs were US$26 billion, mainly from Entresto (sacubitril + valsartan), Kesimpta (ofatumumab), Cosentyx (secukinumab), Kisqali Driven by strong growth in products such as (Liberxilli) and Zolgens.
In terms of specific varieties, the sales of the blockbuster immune drug Cosentyx in the first half of the year reached US$434 billion, a year-on-year increase of 9%; the sales of the anti-heart failure drug Entresto in the first half of the year reached US$218 billion, a year-on-year increase of 32%; these two varieties are still The key drugs driving Novartis' performance grow.
In addition, Sandoz's generics business reported first-half net sales of $7 billion (-1.
In addition, on July 20, Abbott announced its results for the second quarter of 2022, with revenue of $1257 billion, a year-on-year increase of 11%, and net profit of $018 billion, a year-on-year increase of 6In addition, according to its first-quarter 2022 results announced in June, revenue was US$19 billion, a year-on-year increase of 18%; the company's net profit was US$447 billion, a year-on-year increase of 3
Looking ahead, Abbott raised its full-year 2022 EPS guidan.
Abbott expects full-year diluted earnings per share of at least $50 on a GAAP bas.
Adjusted (excluding charges for special items) diluted earnings per share was at least $Abbott also expects testing-related revenue to reach $1 billion for the full year 2022, including $6 billion in sales through June 2022 and $500 million in sales over the next few mont.
According to Biogen’s financial report for the first half of 2022, the company’s total revenue in the first half of 2022 was US$121 billion, down 4% year-on-year; net profit was US$277 billion, down 17% year-on-year; R&D investment was US$08 billion, down 7% year-on-year.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
